Sitravatinib May be the ‘Missing TKI’ for Dedifferentiated Liposarcoma

Commentary
Video

Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.

During Sarcoma Awareness Month 2023, Brian Van Tine, MD, PhD, spoke with CancerNetwork® about the potential of sitravatinib as a treatment for dedifferentiated and well-differentiated liposarcoma; he noted that the agent may become a suitable option in the treatment armamentarium for this patient population.

Van Tine, a professor of medicine in the Division of Oncology, Section of Medical Oncology at Washington University School of Medicine’s Siteman Cancer Center, stated that sitravatinib appears to demonstrate comparable activity with the tyrosine kinase inhibitor pazopanib (Votreint). Based on the observed activity and tolerability of sitravatinib, he said that the agent may be the TKI that this population has been missing.

Van Tine also described the potential next steps for researching and developing this agent, which may include initiating a clinical trial among patients with dedifferentiated liposarcoma.

Transcript:

When we did all the studies of pazopanib [Votrient], which is a different oral tyrosine kinase inhibitor [TKI], it went across all of the sarcomas except liposarcoma, which was left without an oral tyrosine kinase inhibitor that had great activity. What was nice about sitravatinib is that it seems to have activity that is now equivalent to pazopanib in other sarcomas, but in dedifferentiated and well-differentiated liposarcoma.

We found what I would consider the missing TKI for dedifferentiated liposarcoma. And while the development of sitravatinib is still underway and it's not quite FDA-approved yet for another indication, we're hoping that we can still push this TKI through the liposarcoma space because it was clearly active and well tolerated. It's a missing drug in our armamentarium for that one specific disease.

We either need to do a dedicated trial in dedifferentiated liposarcoma or wait for one of the other trials sitravatinib is being used in to read out and then we can use it as a guideline compendium. There needs to be a partnership, especially with the company that owns this agent, so that hopefully we can continue to develop it in this area.

Reference

Ingham M, Lee S, Van Tine BA, et al. A single-arm phase II trial of sitravatinib in advanced well-differentiated/dedifferentiated liposarcoma. Clin Cancer Res. 2023;29(6):1031-1039. doi:10.1158/1078-0432.CCR-22-3351

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The Epione robot eliminates the need for multiple check scans during surgery by allowing physicians to target a tumor with a single button press, according to Govindarajan Narayanan, MD.
The Epione robot may help less experienced surgeons carry out complex cases with a high level of accuracy, says Govindarajan Narayanan, MD.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.
Related Content